Other languages Chemomab Therapeutics Ltd.

Equities

CMMB

US16385C1045

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-28 pm EDT			5-day change	1st Jan Change
0.9088 ^USD	+4.46%		+10.83%	+78.20%

May. 06	Oppenheimer Upgrades Chemomab Therapeutics to Outperform	MT
Apr. 10	Transcript : Chemomab Therapeutics Ltd. - Special Call

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 07
Chemomab Therapeutics Ltd. Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis	Jan. 30
Chemomab Therapeutics Ltd. Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024	Jan. 03
Top Midday Gainers	Nov. 15
Chemomab Therapeutics Ltd. Announces U.S. Food and Drug Administration Grants CM-101 Fast Track Designation for Treatment in Adult Patients of Primary Sclerosing Cholangitis	Nov. 15
Chemomab Therapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis At 2023 Roth MKM Healthcare Opportunities Conference	23-09-28
Chemomab Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis	23-06-28
Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023	23-06-21
Chemomab Therapeutics Ltd. Appoints Nissim Darvish, MD, PhD, as Chairman of the Board Effective June 1, 2023	23-06-05
Chemomab Therapeutics Ltd. Names Adi Mor, Phd as CEO	23-06-05
Chemomab Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Sector Update: Health Care Stocks Edge Above Tuesday Intraday Lows	23-02-21
Sector Update: Health Care Stocks Falling with Broader Tuesday Markets	23-02-21
Chemomab Therapeutics Secures FDA Approval tor Phase 2 Trial of CM-101 for Systemic Sclerosis; Shares Climb	23-02-21
Home Depot's Profit Warning Fuels Premarket Losses for US Equity Futures	23-02-21
Top Premarket Gainers	23-02-21
Chemomab Therapeutics Ltd. Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of Cm-101 in Patients with Systemic Sclerosis	23-02-21
Chemomab Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Chemomab Therapeutics Ltd.

Equities

CMMB

US16385C1045

Other languages

Filters